Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18–30), and high-risk (≥31) categories. Our pi...
Main Authors: | Klein, Molly E, Dabbs, David J, Shuai, Yongli, Brufsky, Adam M, Jankowitz, Rachel, Puhalla, Shannon L, Bhargava, Rohit |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647116/ |
Similar Items
-
The analytical validation of the Oncotype DX Recurrence Score assay
by: Baehner, Frederick L
Published: (2016) -
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
by: Sahebjam, S, et al.
Published: (2011) -
Oncotype Dx Results in Multiple Primary Breast Cancers
by: Toole, Michael J., et al.
Published: (2014) -
Use of Oncotype DX in Women with Node-Positive Breast Cancer
by: Ishibe, Naoko, et al.
Published: (2011) -
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
by: Malo, Teri L., et al.
Published: (2012)